A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Tudor Pop
Michael Rose
Omar Beirat
| Share Statistics | NBIX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $15,545.2 | $286.3 | 83% |
|
| Shares Out (Mil) | 104.2 | 54.2 | 63% |
|
| Institutional Ownership | 98.9% | 92.8% | 83% |
|
| Float (Mil) | 100.4 | 39.7 | 61% |
|
| Beta | 0.39 | 0.94 | 22% |
|
| Avg Daily Volume (000s) | 1,239 | 534 | 74% |
|
| Price Change (52-week) |
15.2% | 58.7% | 58% |
|
| Growth | NBIX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 22.3% | 13.6% | 84% |
|
| Net Income (5yr) | 3.3% | (10.1%) | 45% |
|
| EPS (5yr) | 2.3% | 16.0% | 34 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 43.2% | (15.6%) | 92% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 16 | 16 | 16 | |
| Current EPS | $2.720 | $10.189 | $11.954 | |
| Month Ago EPS | $2.704 | $9.931 | $12.545 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $3.369 | $10.265 | $12.706 | |
| Year/Year Chg | 95.7% | 118.2% | 231.8% | |
| Financials | NBIX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3,374 | $37 | 68% |
|
| Net Income (TTM) (Mil) | $706 | ($43) | 82% |
|
| EPS (TTM) | $7.037 | ($1.400) | 91% |
|
| Operating Cash Flow (TTM) (Mil) | $898 | ($31) | 79% |
|
| Net Cash Flow (TTM) (Mil) | $67 | $2 | 73% |
|
| Long-Term Debt (Q1) (Mil) | $402 | $4 | 56% |
|
| Enterprise Value (Q1) (Mil) | $17,027 | $160 | 81% |
|
| Valuation | NBIX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.21 | 2.77 | 74% |
|
| P/E | 22.4 | 19.1 | 57% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 9.7 | 1.0 | 94% |
|
| Ratios | NBIX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 64.5% | 64.2% | 76% |
|
| Net Margin | 20.9% | (75.9%) | 80% |
|
| ROA | 15.3% | (47.3%) | 94% |
|
| ROE | 22.1% | (55.0%) | 82% |
|
| Liabilities to Assets | 31.1% | 29.6% | 22% |
|
| F-Score | 7 | 2 | 82% |
|
Neurocrine Biosciences, Inc. did not pass any screens on 8/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
